top of page
News & History
2024-11
Study end of clinical validation study in the U.S. at the Bellingham Asthma, Allergy & Immunology Clinic
Identifier: NCT05689307
2024-09
Participation at European Respiratory Society Congress 2024 in Vienna
2024-07
Participation at London Cough Conference 2024 with poster presentation about Cough Detection Algorithm Performance. Preliminary Data from clinical validation study at the Bellingham Asthma, Allergy & Immunology Clinic (USA) was presented.
2023-11
SIVA being used as the first AI-based continuous ambulatory cough measurement system in a global drug development study, providing cough profiles over several weeks
2023-11
Completion of the European Union Medical Device Regulation (MDR) final audit. This will lead to the MDR certificate and CE marking, confirming SIVA Healths' compliance with the highest required regulatory standards.
2023-09
Participation at European Respiratory Society Congress 2023
in Milan
2023-07
SIVA Health AG becoming a fully independent company, owning all the IP generated.
2023-06
Participation at the American Cough Conference 2023 in Washington DC
2023-03
Start of clinical validation study in the U.S. at the Bellingham Asthma, Allergy & Immunology Clinic
Identifier: NCT05689307
2022-09
Poster Presentation at European Respiratory Society Congress 2022 in Barcelona
2022-04
Certification according to EN ISO 13485:2016
2022-03
Poster Presentation at the Swiss Society of Pneumology Congress 2022 in Lucerne
2021-04
Start of clinical validation study at the University Hospital Zurich
First study on continuous cough monitoring over several weeks with a large number of patients
2020-04
Initiation of AI-based continuous ambulatory cough monitoring project in close collaboration with Bayer Pharmaceuticals
bottom of page